You are here: Industry Insights > Heart failure

News List

European Commission approves Jardiance to treat heart failure expresspharma
June 22, 2021
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and ...
Intensive BP Lowering Cuts Major Adverse CV Events, Mortality drugs
May 21, 2021
Intensive blood pressure treatment targeting systolic blood pressure <120 mm Hg results in lower rates of major adverse cardiovascular events and lower all-cause mortality than a standard treatment target among patients at increased cardiovascular risk
Entresto Granted Expanded Indication in Chronic Heart Failure by FDA americanpharmaceuticalreview
February 19, 2021
Novartis announced the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with ...
China approves AstraZeneca’s Forxiga for heart failure pharmaceutical-technology
February 07, 2021
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes.
US approval for MSD’s heart failure med Verquvo pharmatimes
January 22, 2021
The Food and Drug Administration (FDA) in the US has approved MSD’s (known as Merck in the US and Canada) heart failure treatment Verquvo (vericiguat).
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic prnasia
December 17, 2020
Avery Therapeutics and I Peace, Inc. announced a service agreement to advance cell therapy for heart failure.
AstraZeneca’s heart failure treatment Forxiga gets approval in Japan pharmaceutical-technology
December 02, 2020
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Forxiga (dapagliflozin) for treating patients with chronic heart failure (HF) who are receiving standard of care in the country.
Amgen hands back heart failure programme rights to Cytokinetics pharmatimes
November 25, 2020
Amgen has handed back the rights to two investigational heart failure programmes to Cytokinetics after one of the drugs failed to demonstrate impressive results in a phase III study.
Forxiga Approved in the EU for Heart Failure americanpharmaceuticalreview
November 13, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D).
AZ’s Forxiga wins EU approval for heart failure pharmatimes
November 06, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the EU for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).

Previous page 1 2 3 4 5 6 7 Next page